Glaucoma has long been a stealthy thief of sight, often progressing silently until irreversible damage is done. But what if we had a better way to predict, monitor, and manage this condition—beyond traditional intraocular pressure (IOP) readings? Enter Corneal Hysteresis (CH), a biomechanical parameter that is quietly revolutionizing how we understand and treat glaucoma.
Corneal hysteresis (CH) measures the cornea's ability to absorb and dissipate energy. It is the difference between the inward and outward pressure responses of the cornea when deformed, essentially reflecting its viscoelastic properties. Expressed in mmHg, CH values typically range from 10.2 to 10.7 mmHg in healthy eyes. A lower CH suggests a stiffer cornea, while a higher value indicates more resilience.
CH is not just a number; it is a window into the biomechanical integrity of the eye. Studies have shown that lower CH is associated with:
In fact, each 1 mmHg drop in CH can raise the risk of glaucoma by up to 21%.
Three key devices are used to assess corneal hysteresis:
Device | Method | Key Features |
---|---|---|
Ocular Response Analyzer (ORA) | Air puff + electro-optical system | Measures CH, IOPcc (corneal-compensated IOP), CRF (corneal resistance factor) |
Corvis ST | Air puff + high-speed Scheimpflug imaging | Calculates biomechanically corrected IOP (bIOP), indirectly reflects CH |
Brillouin Microscopy | Light scattering | Non-contact 3D imaging; still under exploration for glaucoma use |
Ocular Response Analyzer (ORA) - Reichert Technologies
While Central Corneal Thickness (CCT) has been a traditional risk factor, it is a geometric measure that does not capture the cornea's dynamic behavior. CH offers a more nuanced view. Unlike Goldmann tonometry, which is influenced by CCT, CH-based IOP measurements (such as IOPcc) provide a more reliable insight into true IOP and glaucoma progression.
Multiple studies have confirmed the clinical relevance of CH:
Corneal hysteresis is more than a buzzword; it is a powerful biomarker that deserves a central role in glaucoma care. By integrating CH into routine assessments, clinicians can better stratify risk, personalize treatment, and potentially preserve vision more effectively.
Explore diagnostic technologies like the Reichert Ocular Response Analyzer (ORA) available at Mercoframes Optical Corp, where innovation meets precision in eye care.